| Business Summary | | Luminex
Corporation
manufactures
and
markets
products
incorporating
a
proprietary
technology
that
advances
and
simplifies
biological
testing
for
the
life
sciences
industry.
This
industry
depends
on
a
broad
range
of
tests,
called
bioassays,
to
perform
diagnostic
tests,
to
discover
new
drugs
and
to
identify
new
genes.
The
Company's
LabMAP
technology
allows
its
Luminex
100
system
to
simultaneously
perform
up
to
100
bioassays
on
a
single
drop
of
fluid
by
reading
biological
tests
taking
place
on
the
surface
of
microscopic
polystyrene
beads
called
microspheres.
The
Company's
LabMAP
technology
is
currently
being
used
within
the
various
segments
of
the
life
sciences
industry
in
the
fields
of
drug
discovery,
clinical
diagnostics,
genetic
analysis
and
biomedical
research. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Luminex
Corp.
developes,
manufactures,
and
markets
a
proprietary
technology
that
simplifies
biological
testing
for
the
life
sciences
industry.
For
the
six
months
ended
6/30/01,
revenues
totaled
$8.6
million,
up
from
$2.8
million.
Net
loss
increased
33%
to
$8.3
million.
Revenues
reflect
increased
product
sales
due
to
the
rapid
adoption
of
LabMAP
technology
and
increased
purchases
by
existing
customers.
Higher
loss
reflects
increased
development
and
personnel
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Mark Chandler, Ph.D., 47 Chairman,
Pres, CEO | $350K | -- | Frank Reeves CFO, Exec. VP, Treasurer | -- | -- | Gail Page, 45 COO,
Exec. VP | -- | -- | Michael Bengtson, 43 Exec.
VP, Gen. Counsel, Sec. | 232K | $169K | James Schepp VP
of Sales and Marketing | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|